YD Bio Ltd (YDES) stock
Close on Nov 12, 2026Market cap $367.75MP/E –Yield –
YD Bio Ltd grew revenue 16.9% to $596.82K over fiscal 2025. Free cash flow was -$8.04M. At the latest close the market valued the company at $367.75M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $367.75M
- P/E ratio
- –
- Price to sales
- 616.19
- Price to book
- 82.20
- Dividend yield
- –
- Free cash flow yield
- -2.19%
Fundamentals
- Revenue
- $596.82K
- Net income
- -$8.31M
- EPS, diluted
- -$0.12
- Free cash flow
- -$8.04M
Trading
- Previous close
- $6.15
- Open
- $6.08
- Day's range
- $5.11 – $6.16
- Volume
- 79,429
- Average volume (20 days)
- 109,765
- Beta (5 years)
- 0.12
- 52-week range
- $1.70 – $15.72
- RSI (14 days)
- 44.5
- Volatility (1 year)
- 137.4%
- Relative volume
- 0.34×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | YDES | S&P 500 | Difference | YDES per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.9% | -2.7% | −15.2 pts | ||
| 3 months | +99.8% | -1.7% | +101.6 pts | ||
| Year to date | -57.4% | +11.9% | −69.3 pts | ||
| 1 year | -41.2% | +12.0% | −53.2 pts | ||
| 3 years | -52.8% | +78.2% | −131.0 pts | -22.1% | +21.2% |
| 5 years | -48.9% | +73.2% | −122.2 pts | -12.6% | +11.6% |
Four years at a glance
Fiscal years 2022 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases YD Bio filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About YD Bio
Services-Medical Laboratories
YD Bio Limited is a biotechnology company that develops diagnostic tests and pharmaceutical products. The company focuses on cancer detection and ophthalmic treatments. Its diagnostic portfolio includes blood tests utilizing DNA methylation analysis for pancreatic cancer and breast cancer. In addition, the company develops therapies targeting eye conditions, including dry eye disease, glaucoma, and corneal repair, alongside research into exosome technologies. Its products and diagnostic tests are designed for physicians, patients, healthcare providers, and third-party payors within the medical community.
Company profile, executives and historyYD Bio stock: common questions
What is YD Bio's stock price?
YDES closed at $5.20 on Nov 12, 2026, down 15.53% on the day. Over the past 52 weeks it traded between $1.70 and $15.72.
What is YD Bio's market cap?
YD Bio was worth $367.75M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is YDES's P/E ratio?
YD Bio lost money over fiscal 2025 (diluted EPS -$0.12), so it has no meaningful P/E ratio.
How much revenue does YD Bio make?
YD Bio reported revenue of $596.82K for fiscal 2025, up 16.9% from a year earlier.
Does YD Bio pay a dividend?
No. YD Bio has not paid a cash dividend over the last twelve months.
How has YDES stock performed over the past year?
Including dividends, YDES returned -41.2% over the past year, against +12.0% for the S&P 500.
Who are YD Bio's competitors?
Companies most similar to YD Bio by business, industry and size include ADVB, BGLC, ONCO, SERA, QUCY.
See a number that looks wrong?